Insulet’s (NASDAQ: PODD) web-based diabetes data platform is making its way to the U.S., designed to offer Omnipod users a view into their glucose and insulin trends while providing clinicians a way to deliver personalized recommendations. Dubbed Omnipod Discover, the system made its debut in multiple international markets earlier this year. Ahead of its full […]
Insulet
The 10 largest diabetes tech companies in the world in 2026
Over the last year, a lot has changed in the diabetes technology space. Does that ring true for the rankings of the space’s largest companies? Within the last 12 months, we’ve seen one of the industry’s biggest players separate from its parent company. We’ve also seen significant regulatory milestones, product launches and unveilings of next-generation […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
Insulet slightly lowers 2026 sales growth outlook despite Q2 beats
Insulet (Nasdaq:PODD) slightly lowered its 2026 sales growth guidance despite second-quarter results that handily beat Wall Street estimates. The company previously projected total annual sales growth between 21% and 23%. However, it lowered that outlook by 1 percentage point at each end to 20%-22%. The company did increase its adjusted EPS guidance, though, expecting growth […]
Insulet, Calm partner on emotional well-being resources for diabetes
Insulet (Nasdaq:PODD) announced today that it has partnered with Calm, a leading consumer mental health company. The companies say they are coming together to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. Acton, Massachusetts-based Insulet said the collaboration marks Calm’s first integrated content partnership and collection with a medtech […]
Insulet launches Omnipod 5, Omnipod Discover in Spain
Insulet (Nasdaq:PODD) announced today that it launched its Omnipod 5 insulin pump and Omnipod Discover platform in Spain. With the launch, Spain becomes the 26th country in which Insulet sells Omnipod and the 20th reached by Omnipod 5, the company’s latest-generation patch-based automated insulin delivery system. Omnipod 5 became the world’s first available tubeless, wearable, […]
Insulet adds new board director
Insulet (Nasdaq:PODD) announced today that it appointed Jonathan (“Jay”) Mazelsky to its board of directors, effective July 1. Mazelsky joins the Acton, Massachusetts-based automated insulin delivery technology developer‘s board as an independent director. “We are pleased to welcome Jay to Insulet’s board of directors,” said Insulet President and CEO Ashley McEvoy. “Jay has a strong […]
Insulet has a new chief R&D officer
Insulet (Nasdaq:PODD) announced today on social media that it appointed Dr. Divakar Ramakrishnan as its new chief R&D officer. In a LinkedIn post, the company said Ramakrishnan will lead its R&D organization. His focus centers around strengthening Insulet’s capabilities in delivering innovation around the world. Ramakrishnan joins as the company continues to advance its automated […]
The biggest diabetes tech news out of ADA 2026
The biggest names in diabetes tech gathered in New Orleans last weekend for the American Diabetes Association’s 86th Scientific Sessions (ADA 2026). Clinical findings supporting next-generation automated insulin delivery platforms, continuous glucose monitors (CGMs) and all kinds of other technologies were on display in New Orleans. BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber […]
Insulet data backs Omnipod 6, fully closed-loop AID systems
Insulet (Nasdaq:PODD) today announced new clinical findings for its next-generation Omnipod 6 and fully closed-loop algorithm. The company shared results from its STRIVE pivotal trial and EVOLUTION 3 feasibility study. Investigators presented the outcomes at the American Diabetes Association Scientific Sessions (ADA 2026) in New Orleans. Findings demonstrated meaningful improvements in glucose control for people […]
